Back to results
US 2019/0315871 A1Published application
Methods of treating inflammatory and autoimmune diseases with natalizumab
AssigneeBiogen MA Inc.
InventorIvan Lieberburg
Life of this patent
Estimating the term…
Abstract
Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
Claims17
A method of using natalizumab to treat a patient with an inflammatory or autoimmune disease comprising:
- (a) administering a pharmaceutically effective amount of natalizumab to the patient;
- (b) monitoring the patient for indicators of progressive multifocal leukoencephalopathy (PML), wherein the monitoring comprises serially removing samples of the patient's blood, measuring the amount of IgG anti-JCV antibodies in the samples, and comparing the amount of the anti-JCV antibodies in the samples;
- and
- (c) discontinuing the administration of natalizumab in the presence of indicators of progressive multifocal leukoencephalopathy (PML);
- wherein the monitoring improves the safety of the treatment.
2 more elements
-9. (canceled)
-76. (canceled)
Dependencies are inferred from the claim text.